In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penelope MacRae

Advertisement
Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Lupin Q1 Profit Up 50% But Regulatory Overhang, Slow Product Scale-Up Sparks Concern

Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.

Manufacturing Business Strategies

Aurobindo Expects Sandoz Completion ‘Very Soon’

Aurobindo Pharma says its billion-dollar purchase of Sandoz’s US business is on track for completion “very soon” as it announced net first-quarter net profit that rocketed by nearly 40%, powered by strong US sales.

Deals Sales & Earnings

Mallinckrodt Delays Generics Spinoff

Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.

Strategy Generic Drugs

Deal With Bausch Allows Teva To Sell Generic Of Apriso In 2021

Bausch Health has settled its patent litigation with Teva over the Canadian firm’s ulcerative colitis medicine Apriso (mesalamine) 375mg extended-release capsules. The deal gives Teva the right to market a generic version of Apriso in the US in 2021, nine years before the patent on the drug expires.

Intellectual Property United States

Unichem Joins Growing List of Indian Firms Entering China

Unichem Laboratories has joined a growing list of Indian firms entering China. The firm has set up a wholly-owned subsidiary to sell generic formulations and APIs.

Strategy India

AstraZeneca Seeks To Block Dr Reddy’s US Brilinta Rival

AstraZeneca has petitioned a US court to stop India’s Dr Reddy’s from launching a generic version of its blood clot-fighting drug Brilinta, accusing the Indian drugmaker of patent infringement.

Generic Drugs Legal Issues
See All
Advertisement
UsernamePublicRestriction

Register